Obeidat: A strategic plan to accelerate the access of innovative medicines to patients
Amman2 min read
Share
Director General of the Jordan Food and Drug Administration (JFDA), Dr. Rana Obeidat, affirmed that the institution is working according to development plans to strengthen an integrated regulatory system that contributes to facilitating the access of innovative medicines to patients, with the participation of relevant authorities, thereby consolidating Jordan's position as a regional gateway and raising the competitiveness of the business environment in the pharmaceutical sector.
This came during her meeting with the Multinational Pharmaceutical Group (MPG) in Jordan, headed by Dr. Rami Nassar, and with the participation of members of the administrative board and representatives of member companies, to discuss the latest developments in joint work regarding the strategic plan project aimed at enhancing the attraction of innovative medicines, and attracting medical tourism and global clinical trials.
Obeidat added that the plan contributes to strengthening drug security and providing modern and innovative medicines to patients in Jordan, in addition to attracting medical tourism and global clinical trials, and benefiting from the outcomes of implementing health technology assessment systems, foremost among them the Jordanian Patient Support Program.
She pointed out that the institution will move to activate regulatory harmonization practices by the end of the current year, in addition to studying a project to accelerate the registration procedures for innovative medicines.
For their part, the group's representatives put forward a number of visions and proposals aimed at supporting partnership between global foreign companies and the local industry, in a way that contributes to enhancing the access of innovative medicines to patients, enhancing Jordan's attractiveness for pharmaceutical investments and global clinical trials, and supporting the competitiveness of the pharmaceutical sector and consolidating the Kingdom's position as a regional destination for advanced healthcare.
